Alerta

SYSTEMS AND METHODS FOR SEQUENCE DESIGN

Resumen de: EP4682890A2

A messenger RNA (mRNA) vaccine has emerged as a promising direction to combat the COVID-19 pandemic. This requires an mRNA sequence that is stable and highly productive in protein expression, features to benefit from greater mRNA secondary structure folding stability and optimal codon usage. Sequence design remains challenging due to the exponentially many synonymous mRNA sequences encoding the same protein. The present disclosure presents embodiments of a linear-time approximation (LinearDesign) reducing the design to an intersection between a Stochastic Context Free Grammar (SCFG) and a Deterministic Finite Automaton (DFA). Embodiments of the LinearDesign may implement an mRNA sequence design using much reduced time with very limited loss. Various methodologies, e.g., finding alternative sequences based on k-best parsing or directly incorporating codon optimality, are presented for incorporating the codon optimality into the design. Embodiments of the LinearDesign may provide efficient computational tools to speed up and improve mRNA vaccine development.

PROTEIN AND VACCINE AGAINST INFECTIONS OF SARS-COV-2 OMICRON MUTANT STRAIN XBB AND SUBTYPE THEREOF

Resumen de: EP4682160A1

The present invention relates to a protein and a vaccine against infections by a SARS-CoV-2 Omicron variant XBB and subvariants thereof, which belongs to the medicine field. To address the lack of effective prophylactic and therapeutic agents against the infections caused by SARS-CoV-2 Omicron variant XBB and subvariants thereof, the present invention provides proteins and vaccines against infections by the variants, the vaccines are designed based on the full-length S protein, the receptor-binding domain (RBD) sequence and optimized sequences of SARS-CoV-2 Omicron variant XBB and subvariant XBB.1.5, thereof, which are are capable of aiding the host in combating coronavirus infections, and particularly have a relatively good preventive and therapeutic effect against cross-infections caused by SARS-CoV-2 Omicron variant XBB and subvariants thereof.

COMPOUNDS FOR TREATMENT A CORONAVIRUS INFECTION

Resumen de: US20260015337A1

The present invention is generally directed to inhibitors of SARS-CoV-2-related 3C-like protease (Mpro) useful in the treatment of coronavirus infection and having the Formula (A):

SYNTHESIS METHOD AND APPLICATION OF BENZOTHIASELENAZOLE-1-OXIDE COMPOUND AND DERIVATIVE THEREOF

Resumen de: US20260015332A1

The present invention discloses the synthetic methods and the corresponding applications of a benzothiaselenazole-1-oxide compound and derivatives thereof, in which with sulfoximine and elemental selenium as starting materials, a series of benzothiaselenazole-1-oxide compounds has been synthesized through rhodium-catalyzed direct C—H functionalization reaction. Furthermore, with sulfoximine and elemental selenium as starting materials, a chiral benzothiaselenazole-1-oxide compound is synthesized through direct C—H functionalization reaction by virtue of a chiral phosphoric acid ligand. The present invention can allow specific labeling of sulfydryl structures in polypeptides, carbohydrates, drug molecules, and proteins, as well as in proteins and other biomacromolecules, exhibiting good anti-SARS-CoV-2 activity; and a bioconjugate with trastuzumab according to the present invention can effectively image HER2 receptors on the cell surface and show intense fluorescence, and is applicable to the preparation of an imaging reagent for the HER2 receptors on the cell surface.

RECOMBINANT POLYCLONAL PROTEINS TARGETING COVID-19 AND METHODS OF USE THEREOF

Resumen de: US20260015770A1

Provided herein are compositions comprising recombinant polyclonal proteins (RPPs) derived from mammalian plasma cells and plasmablasts. Also provided are methods of using the RPPs.

REAGENT FOR DETECTING SARS-RELATED CORONAVIRUS

Resumen de: US20260016473A1

The present invention relates to a compound represented by the following general formula (1), or a salt or solvate thereof:in the formula (1), R1, R2, and R3 are as defined in the description.

Protective Apparatuses for Minimizing Risk of Transmission of Infection and Associated Systems

Resumen de: AU2025283415A1

Abstract Disclosed herein are protective apparatuses, and associated systems, for minimizing the risk of transmission of SARS-CoV-2 and/or other infectious diseases between individuals in close proximity to one another including, for example, transmission through droplets projecting from the mouth or nasal region of an infected individual. Said apparatuses may comprise a substantially transparent shield component and a handle component comprising a connecting aspect. The protective apparatuses may comprise light emitting diodes of cool or warm white light and associated control means. The protective apparatuses of the present disclosure may further comprise a camera communicatively connected to a display screen. Abstract ec b s t r a c t e c

SARS-COV-2 VACCINE BOOSTER COMPOSITION

Resumen de: US20260014247A1

The present disclosure provides a composition for inducing or maintaining an immune response against SARS-COV-2 virus.

MRNA FOR SARS-COV-2 S PROTEIN AND USE THEREOF

Resumen de: US20260014248A1

The present invention relates to an RNA encoding the S protein of SARS-COV-2, a vaccine comprising the RNA, and uses thereof. The present invention also relates to a universal polynucleotide molecule comprising a 5′-UTR and/or a 3′-UTR, and a nucleic acid sequence encoding a protein and/or polypeptide of interest, and optionally comprising a polyA.

ENVELOPED VIRUS LIKE PARTICLES COMRISING SARS-COV-2 S PROTEIN

Resumen de: US20260014249A1

Provided is an enveloped virus-like particle (eVLP) comprising a substantially full-length recombinant SARS-CoV-2 spike (S) protein. The eVLP may further comprise an additional recombinant SARS-CoV-2 S protein having a different sequence, another recombinant viral antigen, or a recombinant non-viral protein. The eVLP is derived from an animal cell, such as a CHO cell, expressing the recombinant SARS-CoV-2 spike protein. Also provided are methods of producing such eVLPs, compositions including such eVLPs, and methods and uses for the induction of an immune response against a SARS-CoV-2 spike protein and/or prevention of COVID-19 or SARS-CoV-2 infection, employing such eVLPs.

NEW MERS-COV VACCINE

Resumen de: US20260014245A1

The present invention relates to a mutant receptor-binding domain (MERS-mRBD) of MERS-CoV (middle east respiratory syndrome coronavirus) or a fragment thereof and/or a mutant spike protein (MERS-mSpike) of MERS-CoV or a fragment thereof having a reduced binding strength to the RBD-receptor DPP4 (dipeptidylpeptidase 4) of MERS-CoV compared to the wild type receptor-binding domain of MERS-CoV (MERS-wtRBD) and/or having a reduced binding strength to sialic acid compared to a wild type spike of MERS-CoV (MERS-wtSpike). Furthermore, the present invention relates to and a nucleic acid comprising a nucleotide sequence encoding for the MERS-mRBD or the fragment thereof or the MERS-mSpike or the fragment thereof and a vaccine composition comprising one or more MERS-mRBDs or fragments thereof, one or more MERS-mSpikes, one or more polypeptides or proteins and/or one or more nucleic acids according to the present invention, as well as methods for prevention and/or treatment of diseases caused by MERS-CoV in a subject.

WHOLE BLOOD ASSAY TO MEASURE RESPONSE TO TYPE I IFNS AND DETECT AUTO-ANTIBODIES NEUTRALIZING IFNS

Resumen de: WO2026015635A1

The present invention provides methods, assays and kits for evaluation and assessment of IP-10 (CXCL10) expression, particularly IFN induction of IP-10, to determine the presence of inborn errors of the Type I IFN or Type II IFN response pathway and/or auto-antibodies directed against, and particularly neutralizing, Type I IFNs or Type II IFNs in a patient. The methods, assays and kits including for assessment and evaluation of individuals prior to vaccination with live attenuated virus vaccines, particularly including yellow fever vaccines and COVID-19 vaccines, to assess risk for vaccine-associated disease and adverse events, and for evaluation, treatment and management of patients, particularly including those who develop vaccine-associated disease. Identification of inborn errors of the Type 1 IFN response pathyway and/or auto-antibodies directed against, and particularly neutralizing, Type I IFNs are associated with severe viral illness, including COVID-19 disease, and vaccine-associated disease, particularly with live attenuated virus vaccines, particularly including yellow fever vaccines, as well as arboviral diseases, including WNV and TSE encephalitis.

AUTOMATIC, PORTABLE AND MODULAR EXOSKELETON FOR AN UPPER EXTREMITY

Resumen de: WO2026015035A1

The invention relates to a portable exoskeleton for an upper limb, with n DOF (degrees of freedom), for patients recovering physically from COVID-19, having n DOF, wherein said exoskeleton comprises rigid plates on the outside of the arm which are rigid parts arranged in the upper part; joints (elbow, shoulder, clavicle) which connect the rigid plates and allow their movement in all directions in the form of flexion, extension, abduction, adduction, internal and external rotation; guides arranged on top of each of the rigid plates from the back to the forearm; bus cables for information, which pass through the guides starting from the end of the forearm up to the back; supports (straps) located on rigid plates of the exoskeleton, which secure the structure to the body; sensors connected to the information bus cables which terminate in the embedded system which are arranged in the rigid plates of the linkage points or rigid plates suitably located along the entire arm.

NOVEL CORONAVIRUS PROTECTIVE NASAL SPRAY, AND PREPARATION AND USE THEREOF

Resumen de: EP4678663A1

A fully human ACE2-Fc fusion protein, a pharmaceutical composition, preparation and kit containing same, and a nasal spray containing the fusion protein. Also provided is a use of the fusion protein for broad-spectrum prevention of coronavirus infections, such as infections with coronavirus SARS-CoV-2 and known and unknown variants thereof, including but not limited to original Hu-1, alpha, beta, gamma, delta, mu, omicron, JN.1, and/or other future strains. Also provided are a method for producing the fusion protein, and a method for using the fusion protein to prevent and/or treat infections with coronavirus SARS-CoV-2 and known and unknown variant strains thereof. Further provided is a use of the fusion protein and the pharmaceutical composition and preparation containing same for preventing the spread of coronavirus SARS-CoV-2 and known and unknown variant strains in infected subjects.

NUCLEOCAPSID ANTIGEN IMMUNOTHERAPY FOR COVID-19 FUSION PROTEINS AND METHODS OF USE

Resumen de: AU2024231716A1

The present disclosure provides recombinantly manufactured fusion proteins comprising a SARS-CoV-2 nucleocapsid protein (N-protein) fragment or an analog thereof linked to a human Fc fragment for use in relation to the 2019 Novel Coronavirus (COVID-19). Embodiments include the administration of the fusion proteins to patients that have recovered from COVID- 19 as a booster vaccination, to antibody naive patients to produce antibodies to the SARS-CoV-2 virus to enable the patients to become convalescent plasma donors, to patients who have been infected by the SARS-CoV-2 virus and have contracted COVID-19 in order to limit the scope of the infection and ameliorate the disease, and as a prophylactic COVID-19 vaccine. Exemplary' Fc fusion proteins and pharmaceutical formulations of exemplary' Fc fusion proteins are provided, in addition to methods of use and preparation.

COMBINATION THERAPIES COMPRISING STABILIZED SARS-COV-2 PEPTIDES

Resumen de: WO2024187121A1

Disclosed herein are methods of treating and/or preventing a coronavirus infection using a peptide that binds to a SARS-CoV-2 spike protein and an additional therapeutic agent. Also provided herein are therapeutic combinations comprising a peptide that binds to a SARS-CoV-2 spike protein and an additional therapeutic agent.

FORMULATIONS COMPRISING STABILIZED SARS-COV-2 PEPTIDES AND USES THEREOF

Resumen de: WO2024187120A1

Disclosed herein are dry powders, anhydrous compositions, and emulsions comprising a peptide that binds to a SARS-CoV-2 spike protein. The dry powders, anhydrous compositions, and emulsions disclosed herein are useful for the treatment and/or prevention of a coronavirus infection.

NUTRACEUTICAL FORMULATIONS TO PREVENT, TREAT, AND INHIBIT EXCESS CYTOKINES, SARS-CoV-2 SPIKE PROTEINS, AND mRNA VACCINE SPIKE PROTEIN

Resumen de: US20260007711A1

Combinations of cannabinoids, vitamins, trace elements, bioactive components, bioflavonoid polyphenols, proteolytic enzymes, amino acids, and antioxidants which work independently and synergistically for the prevention, treatment, and inhibition of excess cytokines caused by the immune response to extreme viral and bacterial infections, including the inhibition of COVID-19, Rhinovirus and/or other virus spike proteins and mRNA vaccine spike proteins from attaching to body organ cells, penetrating cell membranes, and the replication of virus particles and spike proteins inside the cells. Inhibition of inflammation and prevention of long-term side effects, health issues (long-haulers), and disease caused by the SARS-COV-2 and its variants, Rhinovirus, other viruses, bacteria, and mRNA vaccines are provided by the nutraceutical compositions. Specific combinations of these compounds work synergistically to increase the efficacy of the independent nutraceuticals in treatment.

NICLOSAMIDE FORMULATIONS AND METHODS OF USE

Resumen de: US20260007622A1

The present invention concerns compositions comprising at least one niclosamide compound, such as niclosamide or a pharmaceutically acceptable salt thereof, and at least one permeability enhancer, such as glycerol or dimethylpalmityl-ammonio propanesulfonate (PPS), and their use of such compositions as niclosamide agents. Advantageously, the niclosamide compound is capable of being transported across a Caco-2 cell membrane by at least 150% relative to the amount capable of being transported across the Caco-2 cell membrane in the absence of the permeability enhancer. Compositions, including oral dosage forms, and methods for delivering niclosamide compounds, such as for treatment or prevention of human coronavirus infections, are also provided.

ROCK2 INHIBITORS FOR THE TREATMENT OF VIRAL INFECTIONS

Resumen de: US20260007673A1

The disclosure provides compositions and methods comprising selective inhibitors of Rho-associated coiled-coil kinase 2 (ROCK2) for use in the treatment of viral infections, particularly coronavirus infections such as SARS-CoV-2, and in the treatment of sequelae resulting from the viral infection, including sequelae resulting from coronavirus infection.

Effect of YEL002 on Conditions and Diseases

Resumen de: US20260007651A1

A preparation comprising the YEL002 compound as an active ingredient for the prevention or treatment of one or more diseases, and methods of using such preparations. The preparations may be a sublingual pill, an injection, dissolved in liquid, dissolved in oil, or any other preparation. The conditions or diseases indicated may be poisoning, radiation poisoning, chemotherapy poisoning, poor vision, peripheral artery disease, smoker's leg, diabetic feet, periodontal disease, varicose or spider veins, blood clots, COVID-19, long COVID, liver disease, symptoms caused by chemotherapy or radiation therapy, hair loss, cancer, inflammation-caused or inflammation-related diseases, autoimmune diseases, infections, and headaches including migraines.

VIRUS DETECTION VIA PROGRAMABLE TYPE III-A CRISPR-CAS SYSTEMS AND METHODS

Resumen de: US20260009092A1

Methods and systems, which use a reconstituted Type III-A CRISPR-Cas system, MORIARTY (Multipronged, One-pot, RNA Induced, Augmentable, Rapid, Test sYstem) for the detection of disease are provided herein. The methods and systems may be performed either without amplification or coupled to RNA transcription as one-pot reactions. The systems and methods herein may be highly sensitive and may be used to detect viruses, including SARS-CoV-2.

METHODS AND DEVICES FOR DETECTING A PATHOGEN AND ITS MOLECULAR COMPONENTS

Resumen de: US20260009789A1

Methods, systems and devices for detecting the presence of a pathogen, for example, a virus (e.g., SARS-CoV-2), or its molecular components, in health care-related samples and/or environmental samples are disclosed. An example system for improving detection of a pathogen includes biosensor device comprising a detection chip and at least one probe that specifically recognizes a pathogen, where the detection chip comprises a graphene field-effect transistor (FET) chip and the probe, which comprises an aptamer, specifically binds to a DNA, RNA, or protein associated with the pathogen.

BISPECIFIC ANTIBODIES THAT BROADLY TARGET CORONAVIRUSES

Resumen de: AU2024300009A1

Disclosed are bispecific antibodies, including dual variable domain immunoglobulins that specifically bind a coronavirus spike protein, such as SARS-CoV-2. Also disclosed is the use of these antibodies for inhibiting a coronavirus infection. In addition, disclosed are methods for detecting a coronavirus in a biological sample, using the disclosed antibodies.

HETEROAROMATIC DHODH INHIBITORS

Nº publicación: AU2024309711A1 08/01/2026

Solicitante:

IMMUNIC AG
IMMUNIC AG

Resumen de: AU2024309711A1

The present relates to novel dihydroorotate dehydrogenase (DHODH) inhibitors of Formula (I) having a carboxylic acid, carboxamide or a bioisosteric moiety and being optionally deuterated, pharmaceutical formulations comprising them, a process for their preparation and their use as medicament, alone or in combination with one or more additional agents, for treating of various diseases, wherein the inhibition of DHODH is desirable (e.g. SARS-CoV-2 or IDH-mutated cancers).